Moderna 4Q Revenues Jump To $571M On Back Of COVID-19 Vaccine; Shares Rise 4%
Shares of Moderna, Inc. jumped 4% in morning trading as the
COVID-19 vaccine manufacturer reported strong 4Q revenues of $571
million versus $14 million in 4Q FY19. Analysts were expecting
revenues of $279.4 million. However, Moderna’s (MRNA) net loss per
share widened to $0.69 versus $0.37 in 4Q FY19. Analysts were
expecting a loss per share of $0.35. Moderna’s CEO Stéphane Bancel
said, “It is encouraging and humbling that more than 32 million
doses of our [Covid-19] vaccine have been administered in the U.S.
and that millions of people around the world have been vaccinated
with our vaccine to date.